FDA
EMA
MHRA
PMDA
Health Canada

Clinical

Phase I
Phase II
Phase III
Readouts
Enrollment Signals

Competitive

Pipeline Tracking
Company Moves
Asset Intelligence
Landscape Reports

Markets

Pricing
Access
Commercial
Launch Tracking

M&A Watch

Licensing
Acquisitions
Partnerships
Capital Raises

Strategy Catalysts Pricing

Humanexa Signals

Data-driven pharmaceutical intelligence for biotech investors, pharma operators, consultants, and intelligence teams.

Company

Pricing
Partner with us
Subscribe
Contact
Privacy

Subscribe to Humanexa Signals

Weekly intelligence for pharma decision-makers.

No paywall. No spam. Unsubscribe anytime.

Intelligence powered by the Humanexa engine.

Asset / Drug

Nemtabrutinib

Drug and asset intelligence for Nemtabrutinib with 4 indexed intelligence signals across regulatory, clinical, competitive, and market developments.

Signals: 2
Catalysts: 2
Stage: Development stage unavailable

Sponsor company

Merck →

Recent signals(2)

ClinicalJuly 11, 2026

Phase II Trial of Nemtabrutinib with CAR T-cell Therapy in Relapsed/Refractory CLL/SLL

A phase II trial is investigating the efficacy of combining nemtabrutinib with lisocabtagene maraleucel in patients with relapsed/refractory CLL/SLL.

ClinicalJune 17, 2026

Nemtabrutinib Study vs Ibrutinib/Acalabrutinib in 1L CLL/SLL Initiated

A study is underway to evaluate nemtabrutinib against ibrutinib or acalabrutinib in treatment-naive CLL/SLL patients.

Upcoming milestones

No catalysts indexed for this entity yet.

Related catalysts(2)

Topline Data

— Nemtabrutinib

July 11, 2026 · N/A

Topline Data

Merck — Nemtabrutinib

June 17, 2026 · N/A

Indications

No related entities indexed yet.

Therapeutic areas

CLL →

Hematology →

Hematology · CLL/SLL →

SLL →

Newsletter

Get signals before the market moves

Concise strategic intelligence on regulatory, clinical, competitive, and market developments — free to subscribe.

No paywall. No spam. Unsubscribe anytime.